February 28, 2017
Chugai Pharmaceutical said on February 27 that its wholly owned subsidiary Chugai Pharma Taiwan has gained approval for its proprietary oral ALK inhibitor Alecensa (alectinib) in Taiwan. Alecensa was approved by the Taiwan Food and Drug Administration for the treatment...read more